Suppr超能文献

相似文献

1
Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells.
Cell Mol Life Sci. 2009 Oct;66(20):3363-73. doi: 10.1007/s00018-009-0108-1. Epub 2009 Aug 8.
2
Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation.
Cell Signal. 2005 Dec;17(12):1477-85. doi: 10.1016/j.cellsig.2005.03.006.
3
Protein kinase CK2 phosphorylates and upregulates Akt/PKB.
Cell Death Differ. 2005 Jun;12(6):668-77. doi: 10.1038/sj.cdd.4401604.
5
CK2 functionally interacts with AKT/PKB to promote the β-catenin-dependent expression of survivin and enhance cell survival.
Mol Cell Biochem. 2011 Oct;356(1-2):127-32. doi: 10.1007/s11010-011-0965-4. Epub 2011 Jul 7.
10
Modulation of Akt kinase activity by binding to Hsp90.
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10832-7. doi: 10.1073/pnas.170276797.

引用本文的文献

3
Circadian Control of Protein Synthesis.
Bioessays. 2025 Mar;47(3):e202300158. doi: 10.1002/bies.202300158. Epub 2024 Dec 12.
4
Mitochondrial ALDH2 improves ß-cell survival and function against doxorubicin-induced apoptosis by targeting CK2 signaling.
J Diabetes Investig. 2024 Jun;15(6):684-692. doi: 10.1111/jdi.14230. Epub 2024 May 7.
5
CK2β Regulates Hematopoietic Stem Cell Biology and Erythropoiesis.
Hemasphere. 2023 Nov 23;7(12):e978. doi: 10.1097/HS9.0000000000000978. eCollection 2023 Dec.
6
SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways.
Exp Mol Med. 2023 Aug;55(8):1757-1769. doi: 10.1038/s12276-023-01062-5. Epub 2023 Aug 1.
7
Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia.
Cancers (Basel). 2023 Jul 21;15(14):3711. doi: 10.3390/cancers15143711.
8
Hyperphosphorylation of hepatic proteome characterizes nonalcoholic fatty liver disease in S-adenosylmethionine deficiency.
iScience. 2023 Jan 14;26(2):105987. doi: 10.1016/j.isci.2023.105987. eCollection 2023 Feb 17.
9
Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.
Front Cell Dev Biol. 2022 Aug 11;10:935023. doi: 10.3389/fcell.2022.935023. eCollection 2022.
10
MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway.
Cancer Biol Ther. 2022 Dec 31;23(1):211-224. doi: 10.1080/15384047.2022.2046450.

本文引用的文献

1
Protein kinase CK2 as a druggable target.
Mol Biosyst. 2008 Sep;4(9):889-94. doi: 10.1039/b805534c. Epub 2008 Jun 12.
2
Protein kinase CK2--a key suppressor of apoptosis.
Adv Enzyme Regul. 2008;48:179-87. doi: 10.1016/j.advenzreg.2008.04.002. Epub 2008 Apr 30.
3
PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival.
Mol Cell. 2008 Apr 25;30(2):203-13. doi: 10.1016/j.molcel.2008.02.024.
4
Protein kinase B: signalling roles and therapeutic targeting.
Cell Mol Life Sci. 2008 Jan;65(1):113-27. doi: 10.1007/s00018-007-7274-9.
5
Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.
Biochim Biophys Acta. 2008 Jan;1784(1):33-47. doi: 10.1016/j.bbapap.2007.08.017. Epub 2007 Aug 30.
6
AKT/PKB signaling: navigating downstream.
Cell. 2007 Jun 29;129(7):1261-74. doi: 10.1016/j.cell.2007.06.009.
9
Protein kinase CK2: a newcomer in the 'druggable kinome'.
Biochem Soc Trans. 2006 Dec;34(Pt 6):1303-6. doi: 10.1042/BST0341303.
10
Discrimination between the activity of protein kinase CK2 holoenzyme and its catalytic subunits.
FEBS Lett. 2006 Jul 10;580(16):3948-52. doi: 10.1016/j.febslet.2006.06.031. Epub 2006 Jun 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验